newsfilter
← Latest News
GlobeNewswire·

Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026

DRTSDRTSW
  • Alpha Tau Medical Ltd. announced that an abstract presenting results from two clinical trials of Alpha DaRT in pancreatic cancer patients at Jerusalem's Hadassah University Medical Center was accepted for an oral presentation at Digestive Disease Week (DDW) 2026.
  • This acceptance marks the first time clinical results of Alpha DaRT in pancreatic cancer have been selected for presentation at a major gastroenterology conference.
  • The abstract, titled "Updated Results of Feasibility, Safety, and Tumor Control in Two First-In-Human Trials of a Novel Alpha-Emitting Radionuclide for Pancreatic Adenocarcinoma," will be presented on Saturday, May 2, 2026, at 10:30 am Central time.
  • The presentation will be led by Principal Investigator Dr. Harold Jacob, Director of Advanced Gastrointestinal Endoscopy at Hadassah University Medical Center, & is based on combined data from two clinical protocols conducted in Israel.
  • CEO Uzi Sofer stated that the acceptance reflects growing recognition of Alpha DaRT's potential to address inoperable pancreatic cancer in locally advanced & metastatic patients.
  • Dr. Jacob noted the technology is designed for delivery by gastroenterologists via Endoscopic Ultrasound (EUS), potentially positioning the specialty at the forefront of a new era in pancreatic cancer therapy.
  • Chief Medical Officer Dr. Robert Den highlighted that the work supports Alpha Tau's clinical development program, including the actively enrolling U.S. IMPACT pilot study & ongoing preparations for a future pivotal study.
  • DDW 2026, the world's premier international gastroenterology conference, will be held from May 2–5, 2026.
  • Alpha DaRT utilizes intratumoral delivery of radium-224 impregnated sources to emit high-energy alpha particles that destroy tumors while sparing surrounding healthy tissue.
  • The press release includes standard forward-looking statements regarding regulatory approval, funding needs, clinical trial outcomes, & other risk factors that could cause actual results to differ materially from expectations.